Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four-to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenografts in animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10 À9 M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/ RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase Ia translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromocGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240718% (Po0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NElike differentiation in culture as well as in vivo and indicate that its production may be important for tumor resurgence following androgen ablation.
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Introduction
Epithelial cells of the human prostate are generally classified as either basal, secretory or neuroendocrine (NE), based on their morphology, location and expression of marker proteins. NE differentiation in prostate cancer (CaP) is of interest, because tumors with a prominent NE component are typically androgen independent and highly aggressive and many CaP are infiltrated with NE-like cells (Abrahamsson, 1999) . NE differentiation is a common feature of prostatic adenocarcinomas and is actually determined by immunoreactivity for NE markers, for example, chromogranin A (CgA), neuron-specific enolase (NSE) or bioactive eutopic hormones such as somatostatin and 5-HT (Abrahamsson, 1999) . NE tumor cells are found at all stages of CaP and can secrete a variety of cytokines and neurohormones (Gkonos et al., 1995) . The increase in NE tumor cell number has been correlated with androgen-independent disease and poor prognosis (Cox et al., 1999) . However, the exact role of NE tumor cells, their bioactive neuropeptides and biogenic amines in disease progression is still not clear and needs further investigations.
The molecular basis by which NE tumor cells arise in prostatic tumors is not understood; however, studies have demonstrated that significant plasticity exists between the adenocarcinoma and NE phenotypes. This suggests that NE tumor cells arise from prostate tumoral cells in response to epigenetic stimuli. NE differentiation can be induced in CaP cells by several means, including interleukin-6 (IL-6), agents that increase levels of intracellular cyclic AMP, and culture in dextran-coated charcoal (DCC)-stripped medium (Cox et al., 2000) .
Adrenomedullin (AM) is a multifunctional peptide with properties ranging from inducing vasorelaxation to acting as a regulator of cellular growth (Hinson et al., 2000) . AM acts through the G-protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity for AM being conferred by the receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) (McLatchie et al., 1998) . AM is expressed in a variety of malignant tissues and was shown to be mitogenic for human cancer cell lines including lung, breast, colon, glioblastoma and prostate lineages in vitro (Ouafik et al., 2002; Nikitenko et al., 2006) . In our laboratory, we had demonstrated the expression of AM in prostate adenocarcinomas with a marked increase in samples with a high Gleason's score suggesting a role of AM in CaP growth and/or differentiation (Rocchi et al., 2001) . We demonstrated that the androgen-independent PC-3 and DU145 cells produce and secrete a great level of AM, and further demonstrated that AM acts as a growth factor for DU145 cells suggesting the presence of an autocrine growth loop. No expression of AM mRNA was found as assessed by northern blot analysis when the LNCaP cells were cultured with medium containing 10% of fetal bovine serum (FBS) (Rocchi et al., 2001) . Recently, barely detectable levels of immunoreactive AM (ir-AM) have been reported in LNCaP cell lines (Abasolo et al., 2003) .
The aim of our study was to investigate the potential role of AM in the differentiation process in CaP by evaluating the effect of AM on the induction of NE phenotype in androgen-sensitive CaP cells. Our results demonstrate that AM, acting through CRLR/RAMP2 and CRLR/RAMP3 receptors, plays a significant role in the acquisition of NE properties by LNCaP cells in vitro and in LNCaP xenografts in noncastrated animals. Moreover, we demonstrate that androgen-sensitive LNCaP cells produce and secrete AM after androgen withdrawal in vitro as well as in LNCaP xenografts after castration of the animals indicating that AM expression is downregulated by androgen. We demonstrate that AM stimulates cGMP in a dose-dependent manner and induces a G-kinase Ia translocation to the nucleus. Furthermore, we investigated whether the cGMP analogue, 8-bromo-cGMP, could mimic the effects of AM on cell differentiation in LNCaP cells. We demonstrate that AM is one of the major factor(s) involved in the NE differentiation induced in LNCaP cells cultured in DCC-stripped medium. Furthermore, the in vivo experiments demonstrate that the effect of AM on tumor growth of LNCaP xenografts depends on the presence or absence of endogenous androgen.
Results
To gain more insight concerning the potential role of AM in CaP, we investigated the effect of AM at cellular and molecular levels on the androgen-responsive prostate cell line, LNCaP, in vitro as well as in vivo in the presence and absence of androgen.
AM receptors expression is not regulated by androgen in LNCaP cells
Total RNA was prepared from LNCaP cells maintained in medium supplemented with either 5% FBS or 5% DCC-stripped serum in the presence or absence of androgen analogue (dihydrotestosterone (DHT); 10
To assess steady-state levels of CRLR, RAMP2 and RAMP3 mRNA transcripts, we used a real-time quantitative reverse transcription (RT)-PCR analysis. The mean levels of CRLR, RAMP2 and RAMP3 mRNAs expression were 3.5970.8, 6.370.9 and 5.5370.5 fg/ng 18S rRNA, respectively. These data demonstrated that LNCaP cells co-express CRLR, RAMP2 and RAMP3 mRNAs ( Figure 1a) . The same pattern of expression was detected in LNCaP xenografts in nude mice (not shown). It is of interest to observe that the expression of CRLR, RAMP2 and RAMP3 mRNAs is not regulated by androgen status at the post-transcriptional level ( Figure 1a) .
To confirm the expression of CRLR, RAMP2 and RAMP3 proteins, cell extracts (40 mg of protein) of LNCaP cells maintained in the presence of 5% FBS (Figure 1b , lanes 1, 5 and 9) or 5% FBS þ 10 À9 M of DHT ( Figure 1b , lanes 2, 6 and 10) or 5% DCC (Figure 1b , lanes 3, 7 and 11) or 5% DCC þ 10 À9 M of DHT (Figure 1b, lanes 4, 8 and 12) or tissue extracts from xenografts were subjected to western blot analysis ( Figure 1c, lanes 1, 3 and 5 ). LNCaP cells produced CRLR as a distinct band of 48 kDa and multimer, presumably heterodimers CRLR/RAMP2 or CRLR/ RAMP3, at 73-76 kDa (Figure 1b, lanes 1-4) . RAMP2 and RAMP3 were seen as a monomer of 28 kDa and multimer, presumably homodimer at 50 kDa and heterodimer at 73-75 kDa, as it was shown for CRLR (Figure 1b, . No changes can be observed at the protein levels for CRLR, RAMP2 and RAMP3 after DHT treatment at 10 À9 M, demonstrating that androgens do not regulate these genes at the translational and/or post-translational levels ( Figure 1b) . The same data were observed when LNCaP cells were treated with 10 5 and 9 ) or 5% FBS þ 10 À9 M of dihydrotestosterone (DHT) (lanes 2, 6 and 10) or 5% of dextran-coated charcoal (DCC) (lanes 3, 7 and 11) or 5% DCC þ 10 À9 M of DHT (lanes 4, 8 and 12) were separated on 12% of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to Hybond-C membrane and immunoblotted using antibodies generated against CRLR, RAMP2 and RAMP3 peptides as described (Fernandez-Sauze et al., 2004) . (c) Protein extracts prepared from LNCaP xenografts were treated as described in (b). Staining for all samples was blocked by the addition of 20 mg/ml CRLR, RAMP2 and RAMP3 peptides (lanes 2, 4, and 6). To assess the amount of proteins loaded for each sample, immunoblot analysis was performed with anti-b-actin. Figure 2d ) resulted in the loss of neuritic processes and the reacquisition of a morphology typical of untreated cells. Neuritic branching was used as a direct measure of neuronal morphogenesis in response to neurogenic factors (Costantini and Isacson, 2000) and was used to quantitate the influence of AM and Epi on the acquisition of the neuritic morphology ( Figure 2g ). We found that while untreated LNCaP cells normally exhibit short rarely branched cellular processes, the cells treated with AM or Epi exhibit neuritic branching 2.5-to 3-fold greater, respectively ( Figure 2g ).
To elucidate the type of AM receptors involved in the NE differentiation process, experiments were performed with AMR antibodies (anti-CRLR/anti-RAMP2 and anti-CRLR/anti-RAMP3) that were shown to block the binding of labeled We further tested the effect of AM on the growth and/or NE differentiation of LNCaP xenografts in vivo in the presence (non-castrated animals) or absence (castrated animals) of androgen. Mice bearing LNCaP xenografts received either an intratumoral administration of 50 ng of AM per day (n ¼ 8) or a saline solution (n ¼ 8) as control. The tumor volume showed no significant difference between control and AM-injected tumor xenografts ( Figure 4a ). These results suggest that in noncastrated animals, AM cannot stimulate a tumor growth of androgen-sensitive CaP, but rather could be involved in the development of NE phenotype in vivo. Accordingly, the proliferative indices measured after staining for Ki-67 nuclear antigen revealed no significant difference between AM-treated and control tumors (P>0.5; Figure 4b ). Interestingly, the NSE levels in serum was significantly increased (Po0.001 after 32 days of treatment) in the AM-treated group (Figure 4c ). To confirm further these data, control and AM-treated xenografts were immunostained using anti-NSE and anti-CgA antibodies. The data demonstrate a clear increase in the signal intensity and immunostained surfaces for both markers after AM treatment as compared to control ( Figure 4d ). The quantification revealed a significant increase in AM-treated tumors as compared to controls (Po0.01 for NSE and Po0.001 for CgA; Figure 4e ). These data demonstrate that in the presence of androgen, AM induces NE phenotype in vivo and stimulates the synthesis and secretion of NE markers in vivo.
Regulation of AM expression by androgen in vitro and in vivo Radioimmunoassay (RIA) of medium conditioned by LNCaP cells in the presence of either 5% FBS or 5% DCC-stripped media demonstrated that ir-AM accumulated in medium over a 12-day period, reaching 2275 pg/ml/24 h/1 Â 10 5 cells and 126710 pg/ml/24 h/ 1 Â 10 5 cells, respectively (Figure 6a ). In contrast, AM was barely detectable (o671 pg/ml/24 h/1 Â 10 5 cells) in the presence of DHT at 10 À9 M (Figure 5a ). To determine whether AM levels were related to cellassociated AM levels, RIA was performed on cell lysates (Figure 5b ). In these lysates, the quantity of endogenous AM was unaffected by exogenous AM added to the whole cells under permissive conditions for ligand binding and internalization (371C), or for ligand binding alone (41C) ( Table 1) . Thus, cell surface-bound or internalized AM did not contribute to the peptide levels assayed in cell lysates. The lysates levels, therefore, represented unsecreted, intracellular AM. Intracellular AM accumulated in prostate cells was deprived of androgens (2574 ng/mg protein), whereas androgenstimulated cells demonstrated very low levels of AM (371 ng/mg protein) over a 12-day period; thus, AM secretion reflected the intracellular quantities.
To assess the steady-state levels of AM mRNA transcripts, total RNA was prepared from LNCaP cells cultured in the presence of 5% FBS, 5% DCC, 5% DCC þ DHT at 10 -9 M, or from LNCaP tumor xenografts (control and after castration). LNCaP cells cultured in 5% DCC resulted in a (770.5)-fold (n ¼ 6; mean7s.e.m.) increase of AM mRNA levels compared with 5% FBS condition (Po0.01; Figure 5c ). The treatment of the LNCaP cells with DHT at 10 À9 M reduced AM mRNA levels to FBS value, suggesting that AM mRNA levels are downregulated by androgen analogues (Figure 5c ).
To determine whether AM expression can be regulated by androgen status in vivo, the effect of castration on AM expression in xenografts was assessed ( Figure 6 ). In the castrated mice, AM mRNA levels increased by approximately 4.870.2-fold (n ¼ 20; mean7s.e.m.) as compared to controls (Po0.01; Figure 6 ). RIA demonstrated that castration increased ir-AM levels by 3.2370.03-fold (n ¼ 20; mean7s.e.m.) being 225712 pg/ mg protein in castrated animals and 69.773 pg/mg protein in controls (Po0.01; Figure 6 ).
AM produced and secreted in DCC-stripped medium is involved in the NE differentiation of LNCaP cells in vitro Serum deprivation induces NE characteristics of LNCaP cells in vitro. We hypothesized that AM produced and secreted under 5% DCC may be involved in the observed neuron-like morphology (Figure 7a ). To test this hypothesis, LNCaP cells were exposed to either anti-AMR or anti-AM antibodies (30 mg/ml). These treatments strongly prevented NE phenotype by inhibiting the autocrine/paracrine loop, which involves the secreted AM and its receptors (Figures 7c and d) . Interestingly, anti-AMR antibodies acted in a doserelated manner (Figure 7g ), indicating that AM must act via CRLR/RAMP2 and RAMP3 complexes. The addition of the pre-immune affinity-purified IgG at 30 mg/ml did not prevent the NE phenotype (Figures 7f  and g ). The same inhibition of NE phenotype was observed using the AM antagonist AM 22À52 at 10 À6 M (Figures 7e and g ). Furthermore, the relative quantification of western blot analysis demonstrate the decrease of NSE levels upon treatment with anti-AM and anti-AMR antibodies as compared to control cells (Po0.001; Figure 7h ). Collectively, these results demonstrate clearly that AM might be one of the major factors produced and released by LNCaP cells in the absence of androgen and might act as paracrine and autocrine regulators of neuron-like differentiation of prostate cell.
Signaling pathway activated by AM: effect of AM on cGMP production Exposure of LNCaP cells to AM at 10 À7 M induced a four-to fivefold increase in cGMP content and reached AM induces NE phenotype in androgen-sensitive LNCaP cells C Berenguer et al AM induces nuclear translocation of G-kinase Ia Unlike cAMP, which acts predominantly through Akinase activation, cGMP has several intracellular target proteins, that is G-kinase, cGMP-gated ion channels and cGMP-stimulated or cGMP-inhibited phosphodiesterase (Butt et al., 1993) . Several groups have shown nuclear translocation of G-kinase I in cGMP-treated cells (Pilz and Casteel, 2003) . Accordingly, we examined whether AM induces nuclear translocation of G-kinase Ia and Ib using antibodies specific for each. LNCaP cells were treated for up to 4 h with AM (2 Â 10 À7 M) before immunostaining for G-kinase Ia and Ib separately. The data showed that AM induced nuclear translocation of Gkinase Ia (Figure 9 ). Exposure of LNCaP cells to AM showed a nuclear staining for G-kinase Ia as early as 1 h ( Figure 9b) ; nuclear staining was maximal at 4 h, where nuclear G-kinase Ia was detectable in 93% of the AMtreated cells (Figure 9d ) and persisted for more than 4 h in the presence of AM as compared to control cells (Figure 9 ). Pretreatment of LNCaP cells with AM antagonist AM 22À52 (10 À6 M) or Ptox (10 ng/ml) prevents AM to induce a nuclear translocation of G-kinase Ia (Figures 9e and f) .
In cells treated with AM for 4 h, washed and returned to stimulant-free culture media, intense nuclear G-kinase Ia staining was still observed for up to 8 h later (not shown). The presence of nuclear G-kinase Ia, many hours after the removal of exogenous AM, may be due to lack of nuclear export and a long half-life of the nuclear kinase. No nuclear translocation of G-kinase Ib in LNCaP cells can be observed after AM treatment (not shown).
Effect of the protein kinase G inhibitor KT-5823 on NE phenotype
To demonstrate further that AM induced neurite outgrowth by activating PKG, LNCaP cells were AM was assayed by radioimmunoassay (RIA) in the medium to determine the secreted AM and cell lysates to determine intracellular peptide levels from 5% of fetal bovine serum (FBS) (hatched bars), androgen-deprived (filled bars) and androgenstimulated (dashed bars) cells. AM levels in the medium were at the limit of detection for all androgen-supplemented cells. Positive results indicate that the majority of plates at a given time point contained AM levels above the limit of detection. (c) Real-time quantitative reverse transcription (RT)-PCR analysis of AM mRNA levels. Total DNA-free RNA (1 mg) from LNCaP cells were reverse transcribed to cDNA and subjected to quantitative RT-PCR using the LightCycler system for the estimation of relative AM to ribosomal 18S rRNA ratio as described in Materials and methods. Data are presented as mean7s.e.m. of four independent experiments (**Po0.01). Figure 5c . Data are presented as mean7s.e.m. of four independent experiments (**Po0.01). LNCaP xenografts extracts prepared from control (n ¼ 10) and castrated (n ¼ 20) mice were subjected to radioimmunoassay (RIA) to determine the immunoreactive AM (ir-AM) levels (**Po0.01).
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C Berenguer et al pretreated with AM (2 Â 10 À7 M) and selective PKG inhibitor. The PKG inhibitor KT-5823 at 10 À6 M markedly inhibited the NE phenotype induced by AM (Figures 10b and c) and DCC-stripped medium (Figures  10d and e) . Interestingly, cells treated with PKG inhibitor are organized in clusters (see Figures 10c and e) .
In the absence of androgen, AM promotes CaP tumor growth To investigate further whether the presence of endogenous androgen in vivo might prevent somehow the action of AM on tumor growth, experiments were realized with three groups of castrated animals, which received daily an intratumoral (50 ng), or intraperitoneal (1.5 mg) administration of AM, or saline vehicle, respectively. The growth of xenografts was significantly increased in both groups treated with AM as compared to control group (Figure 11a ). After 32 days of treatment, a group of animals were killed, and tumor size and vascularity were assessed. The xenografts treated with AM were large, red and hypervascular with many visible surface blood vessels, whereas control xenografts were less vascular. At 32 days of treatment, the mean tumor volumes in the control, it-AM and ip-AM groups were 10007235, 24177185 and 34807354 mm 3 , respectively, (Figure 11a ). Immunostaining with CD31 demonstrates that tumors treated with AM are more hypervascular than tumors treated with saline (not shown). The mean vessel area was significantly higher in the AM-treated tumors as compared to control tumors (Po0.01; Figure 11b ).
Discussion
Mechanisms that evoke the multiple cell phenotypes encountered in human tumors are poorly understood. Peptide growth factors and cytokines, operating either within the context of androgen-dependent signaling mechanisms or in an androgen-independent context, are likely to be critical to the process of CaP progression. Our study shows that (i) LNCaP cells express CRLR, RAMP2 and RAMP3 mRNAs encoding AM receptors independent of androgen status; (ii) AM is produced by LNCaP cells upon the removal of androgen and may function as a mediator of NE-like differentiation in culture as well as in vivo; (iii) loss of AM induces NE phenotype in androgen-sensitive LNCaP cells C Berenguer et al NE phenotype of LNCaP cells upon the withdrawal of AM, or its neutralization by anti-AM or anti-AMR antibodies suggests that the phenotype of NE cells within tumors is dynamic and will be determined in part by the balance of differentiative and mitogenic factors in the local environment; (iv) increase in cGMP levels by AM induced a nuclear translocation of cGMP-dependent protein kinase (PKG Ia). The effects of AM and 8-bromo-cGMP were blocked by the protein kinase G inhibitor KT-5823. Our findings are novel because they Before the addition of AM, cells were treated with pertussis toxin (Ptox) (e) or AM antagonist AM 22À52 (f) for 1 h. Cells were fixed and stained as described under Materials and methods with a G-kinase Ia specific antibody and a fluorescently labeled secondary antibody. Photographs were taken with a Â 40 objective lens; the bar represents 20 mm.
AM induces NE phenotype in androgen-sensitive LNCaP cells C Berenguer et al identify a new and unanticipated role of AM in NE-like differentiation of prostatic cancer cells. NE phenotype as well as NSE expression was reduced by the addition of anti-AM or anti-AMR antibodies in vitro, indicating that AM is clearly involved in these processes. Interestingly, injection of AM in tumor xenografts in vivo in noncastrated animals induces a clear increase of NSE expression in tumors and circulating NSE in serum. The same finding was observed for the expression of CgA in the tumors xenografts. Serum measurement of NE markers such as NSE does better reflect the entire NE tumor cell population, NE differentiation has been proven to correlate with tumor progression (Abrahamsson, 1999) . There are several studies that show correlation between CgA and NSE serum levels, androgen independence, progression of the disease and prognosis. Based on our data, it seems that AM could be involved in progression of the CaP disease toward an androgen independence status.
Another result of great importance concerns the downregulation of AM expression by androgens in vitro as well as in vivo. Interestingly, the expression of AMR is not regulated by androgen, suggesting that the involvement of AM system in situ is modulated by regulating the AM levels. We also brought evidence of the presence of autocrine loop that involves AM and its own receptors selectively in hormone-deprived cells, suggesting that foci of AM-producing cells in a tumor could stimulate cells expressing AM receptors via autocrine and paracrine mechanisms. The barely detectable levels of AM in androgen-stimulated LNCaP cells and xenografts controls prior castration demonstrate that androgens primarily negatively regulate AM synthesis.
To determine the signaling pathway activated by AM in LNCaP cells, many cases have been studied. First, we demonstrate the generation of cGMP and the translocation of cGMP-dependent protein kinases (PKG), the major intracellular cGMP target in many cell types (Pilz and Casteel, 2003) , in the nucleus in response to AM. cGMP can regulate transcription factors directly by inducing phosphorylation or by increasing expression of short-lived proteins. Transcriptions factors whose expression is regulated by cGMP include the AP-1 family proteins c-fos and junB, the early growth response gene Egr-1 and the growth arrestspecific homeobox (Gax) gene (Pilz and Casteel, 2003) . Nuclear translocation of PKG has been demonstrated in neuronal cells, neutrophils, macrophages and some embryonal smooth muscle cells (Pilz and Casteel, 2003) . Taken together, our data demonstrate that PKG plays an important role during LNCaP phenotypic modulation in response to AM, positively and negatively regulating gene expression.
Second, our data indicate that the signaling through extracellular signal-regulated kinase extracellular signalregulated kinase-1 (Erk1), Erk2, STAT1, -2, -5 and -6, PKC, stress-activated protein kinase (SAPK)/Jun Nterminal kinase (JNK) and PI3K pathways is not activated by AM, suggesting that AM does not act through these pathways (not shown). Our results suggest that the mechanism of IL-6 and HB-EGF-mediated NE differentiation (Chung et al., 1999; Kim et al., 2002) differs from the AM-induced mechanism as AM does not induce the phosphorylation of STAT3 at either Ser 727 or Tyr 705, the latest site shown to be critical to the differentiation event (Spiotto and Chung, 2000) , nor the activation of the Erk-mitogen-activated protein kinase (MAPK) pathway. As in the case of HB-EGF, AM also did not induce cell cycle arrest as it was seen with IL-6. This last finding is potentially physiologically significant because it implies that cells exhibiting features of NE differentiation in vivo need not necessarily exit the cell cycle as suggested previously (Blutt et al., 1997) . 
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Foci of AM-producing cells in a tumor could stimulate cells expressing AM receptors via autocrine/ paracrine mechanisms. The presence of AM receptors in CaPs confirms that AM must play a role in situ. AM has been shown to be involved in carcinogenesis and tumor progression by promoting tumor proliferation, inhibiting apoptosis (Nikitenko et al., 2006) and promoting angiogenesis (Fernandez-Sauze et al., 2004) . All these activities may be relevant in prostate physiology and physiopathology. The data reported in this study demonstrate that the nature of effect of AM on CaP tumor growth depends on the presence or absence of androgens. As discussed above, in in vivo model in the presence of androgen AM induces an NE differentiation suggesting that androgen must act on tumor microenvironment by activating a signaling in all androgen sensitive cells to prevent somehow AM to stimulate a tumor growth rate. In the absence of androgens in vivo, AM was able to stimulate the growth of LNCaP xenografts at least indirectly by stimulating the formation of large functional blood vessels in the tumor tissues, leading to the nutrient and oxygen supply. These findings are consistent with our previous report demonstrating that the neutralization of AM by intratumoral injection of the anti-AM antibody suppressed the in vivo growth of glioblastoma cell line partly by suppressing the formation of functional large blood vessels (Ouafik et al., 2002) . In a recent work in the laboratory, we found that AM acts as a potent autocrine/paracrine growth factor for human androgen-independent DU145 cell line in vitro and that its inhibition suppresses tumor growth in vivo (Berenguer et al., manuscript in preparation) . Recent data by Abasolo et al. (2003) demonstrate that overexpression of AM cDNA markedly inhibits proliferation of PC3 CaP cells in vitro and in vivo.
In conclusion, we demonstrate that AM is a mediator of the NE phenotype in CaP. The finding that the protein is substantially induced with androgen withdrawal in vivo and the fact that in the absence of androgen, AM can promote a tumor regrowth in hormonoindependent manner is interesting and potentially clinically important.
Materials and methods

Cultured cells
The human CaP cell line LNCaP fast growing colony (FGC) was purchased from American Type Culture Collection (Rockville, MD, USA) and cultured in RPMI 1640 (Invitrogen Life Technologies Inc., Paris, France) as described (Rocchi et al., 2001) . For morphological studies, cells were maintained in growth medium supplemented with 5% FBS or 5% DCCstripped serum without phenol red until use. After 48 h, the cells were treated for four or six consecutive days with daily replacement of medium and the following compounds: AM (2 Â 10 À7 M; Bachem, Bubendorf, Switzerland), AM 22À52 antagonist (10 À6 M; Bachem), DHT (10 À9 M), b-adrenergic receptor agonist Epi (10 À5 M), inhibitor of cGMP-dependent protein kinase (PKG inhibitor KT-5823 at 10 À6 M; Euromedex, Souffelueyersheim, France), 8-bromo-cGMP 10 À4 M (Calbiochem/VWR, Fontenay SOUS Bois Cedex, France ), AM receptor antibodies (anti-AMR: anti-CRLR/anti-RAMP2 or anti-CRLR/anti-RAMP3) or pre-immune serum (affinitypurified IgG) at 30 mg/ml.
Experimental protocol for animals
The s.c. tumors were generated by injection of 5 Â 10 6 LNCaP cells mixed at a 1:1 dilution with Matrigel (BD Biosciences Europe, Le Pont-DE-Claix Cedex, France) in the right flank of male athymic Naval Medical Research Institute (NMRI) (nu/nu) nude mice (Harlan, Gannat, France). Tumor size was measured weekly in three dimensions using calipers as described (Ouafik et al., 2002) . At a tumor volume of B100 mm 3 , mice were randomized into two groups that received injection of phosphate-buffered saline (control, n ¼ 8) or s.c. injection of AM around the tumor (50 ng/day). At the indicated time, blood was taken for NSE assay. At a tumor volume of B600 mm 3 , mice were killed and tumors were removed for immunohistochemistry and western blot analysis. To see whether AM expression is modulated by androgen status in vivo, mice bearing tumors (700-800 mm 3 ) were used as ) were subcutaneously implanted in nu/nu mice. After 3 months, when the primary tumors were 400-500 mm 3 in size, animals were castrated and randomly divided into three groups. Mice bearing LNCaP tumors were treated with AM by intratumoral (50 ng) or intraperitoneal (1.5 mg) administration or saline vehicle. The sizes of the LNCaP xenografts were determined as described in Figure 4a . Tumors sections were immunostained with CD31 in control and intraperitoneal AM-treated tumors (not shown). (b) Quantitative assessment of the mean vessel area expressed in mm 2 was measured through a microscope using an NIH image 1.62 Software for analysis (n ¼ 8; values represent the mean7s.e.m.; **Po0.01).
AM induces NE phenotype in androgen-sensitive LNCaP cells C Berenguer et al control (n ¼ 10) or castrated (n ¼ 20). At the end of the experiment, tumors were removed for total RNA preparation and peptide extraction for AM RIA (see in the following text), snap-frozen in liquid nitrogen and stored at À801C. In the last series of experiment, mice bearing LNCaP tumors (B600 mm 3 ) were castrated and separated into three groups. The animals received either a saline injection (n ¼ 6) or an intratumoral injection of 50 ng of AM per day (n ¼ 6) or an i.p. injection of 1.5 mg of AM per day (n ¼ 6). Postcastration tumor responses in the presence or absence of AM were observed by measuring tumor volume twice a week. At the end of the experiment, the mice were killed by neck dislocation and tumors were processed as described above.
NSE assay
For quantitative determination of NSE in mice serum, the electrochemiluminescence immunoassay 'ECLIA' was performed using the Roche Elecsys 2010 immunoassay analyzer (Roche Diagnostics GmbH, Mannheim, Germany) according to the supplier's protocol.
Morphological analysis
Live LNCaP cells were imaged by photomicroscopy using phase contrast optics IMT2 (Olympus SCOP, Anthony, France) through a color tri-CCD camera (JVC) and analysed with NIH Image 1.62 software. The numbers of neuritic branch points and cells bodies were counted in photomicrographs of random fields of each treatment and expressed as branch points per 100 cells. The data presented are the mean derived from counting at least 300 cells per treatment.
Peptide extraction and radioimmunoassay
LNCaP cell extracts, medium and LNCaP xenografts were prepared for RIA of AM as previously reported (Rocchi et al., 2001) .
RNA preparation and real-time quantitative RT-PCR Total RNA was extracted from LNCaP cells and reverse transcribed to cDNA as described (Rocchi et al., 2001) . Realtime quantitative RT-PCR method was used to accurately detect the changes in the expression of the described genes as described (Ouafik et al., 2002) . The levels of human AM mRNA and 18S rRNA were determined as described (Rocchi et al., 2001) . Human CRLR, RAMP2 and RAMP3 were amplified (CRLR: forward primer 5 0 -ACCCCTTCAACAAG CAGAA-3 0 and reverse primer 5 0 -TCAGTTCCTGCTG CAACATC-3 0 ; RAMP2: forward primer 5 0 -GACGGTGAA GAACTATGAGACAGC-3 0 and reverse primer 5 0 -GCTA TAAGGCCTGCTAATCATGG-3 0 ; RAMP3: forward primer 5 0 -TCTGGAAGTGGTGCAACCTGT-3 0 and reverse primer 5 0 -GATGCCGGTGATGAAGCC-3 0 ), detected and quantitated in real-time using LC 480 PCR system (Roche Diagnostics, Meylan, France). The amplification mixture contained cDNA derived from 50-150 ng of total RNA and 0.2 mM of primer and 0.1 mM of Taq Man probe (CRLR, we used universal probe library probe: Human # 21 cat. no. 04686942001; RAMP2, 5 0 -TGGATCCTATCGAAAAGGAT TGGTGCG-3 0 ; RAMP3, 5 0 -AGATGGAGGCCAATGTCGT GGGCT-3 0 ). A two-step PCR was performed with denaturation at 951C for 15 s, and annealing/extension at 601C (651C for RAMP2) for 30 s for 40 cycles. The reaction produced an 85-bp PCR product for CRLR, one of 114 bp for RAMP2, one of 130 bp for RAMP3 and one of 70 bp for 18S. For quantitation of the data, AM, CRLR, RAMP2 and RAMP3 mRNA levels were normalized to the 18S rRNA levels as previously described (Rocchi et al., 2001 ).
Western blot analysis
Cell pellets or tissue xenografts were prepared and processed for western blot analysis as described (Ouafik et al., 2002) . Immunoblotting for CRLR, RAMP2 and -3 was performed using 1/250 dilution of specific rabbit antiserum as previously described (Fernandez-Sauze et al., 2004) . A polyclonal antihuman NSE and anti-b-actin antibodies (Cytoskeleton Inc./ Tebu Bio, Le Perray EN Yvelines, France) were used at 1/200 and 1/1000 dilutions, respectively. Signals were revealed using an enhanced chemiluminescence kit (ECL Kit, GE Healthcare, Europe GmbH, Orsay Cedex, France).
Immunohistochemistry and microscopic analysis of chromogranin A and NSE Sections (5 mm) were cut from formalin-fixed paraffin-embedded LNCaP xenografts. Immunohistochemistry was performed using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) as previously described (Rocchi et al., 2001) . Optimal dilution for monoclonal antibodies against NSE, CgA, CD31 and Ki-67 (Dako, Glostrup, Denmark) were used at a dilution of 1:200, 1:200, 1:40 and 1:40, respectively. The surface of staining with NSE and CgA was measured with NIH image 1.62 Software by using HSV transform and automatic threshold on the hue component.
cGMP assay LNCaP cells treated with AM (10
À7
-10 À9 M) in the presence or absence of Ptox (10 ng/ml) were prepared to measure the intracellular amount of cGMP using the cGMP enzyme immunoassay Biotrak (EIA) System (GE Healthcare) according to the supplier's protocol.
Immunofluorescent staining of G-kinase Ia and Ib
Cells were fixed with 4% of paraformaldehyde for 10 min and washed three times with phosphate buffer (pH 7.4). After blocking with 3% of normal sheep serum (NSS) for 2 h, cells were incubated with rabbit polyclonal antibodies at 1:800 against G-kinase Ia (KAS-PK005) and G-kinase Ib (KAP-PK002) (Stressgen Biotechnologies Corporation, Victoria, Canada) in the presence of 1% NSS overnight at room temperature. After washing with phosphate buffer, Alexa fluor 488 conjugated goat anti-rabbit immunoglobulin G (IgG) at 1:200 (Invitrogen Life Technologies Inc.) was added for 2 h at room temperature. Cells were visualized with a Nikon fluorescence microscope using appropriate filters.
Data analysis
Results are depicted as the mean7s.e.m. from at least three independent experiments. Statistical significance of paired treatments was assessed by a one-way analysis of variance followed by Fisher's PLSD test (ANOVA, Statview 512, Brain Power Inc., Calabasas, CA, USA).
